Skip to main content

Table 1 CK18-Asp396 and total CK18 levels in plasma of CRC patients.

From: Circulating cell death products predict clinical outcome of colorectal cancer patients

  P1 (n = 49) P2 (n = 20) P3 (n = 28)
Mean time to operation (days, range) -13 (-50-0) +20 (7–60) +137 (82–364)
CK18-Asp396 level (U/l)    
Median (IQR) 59.1 (41.5–88.2) 74.8 (39.7–107.9) 55.6 (42.1–79.9)
P-value   0.02 vs P1 0.11 vs P2
Total CK18 level (U/l)    
Median (IQR) 260.5 (181.6–378.3) 308.1 (208.7–492.3) 257.2 (183.8–457.2)
P-value   0.08 vs P1 0.05 vs P2
  1. CK18-Asp396 and total CK18 levels in plasma of colorectal cancer patients. Wilxocon signed-rank tests were used to compare paired observations. P ≤ 0.05 were considered significant, shown in bold. P1 = pre-operative plasma, P2 = post-operative plasma shortly after operation, and P3 = post-operative plasma longer after operation.